Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 9/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | MC1R | Q01726 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427392 | 0.93 | F2 (0.35) | AGTR2F2CYP3A4THRBHSD17B10 | |
| SCHEMBL8230204 | 0.87 | F2 (0.34) | AGTR2F2CYP3A4THRBHSD17B10 | |
| SCHEMBL4294862 | 0.84 | ACE (0.40) | AGTR2F2CYP3A4THRBHSD17B10 | |
| Hydrochloric Acid SCHEMBL4304725 | 0.83 | AGTR2 (0.40) | AGTR2CYP3A4THRBHSD17B10MC4R | |
| SCHEMBL2427394 | 0.83 | CYP3A4 (0.34) | F2CYP3A4THRBHSD17B10NAAA | |
| SCHEMBL2429307 | 0.79 | ABCB1 (0.34) | AGTR2MC4RMC3RMC1RPRMT3 | |
| SCHEMBL2426240 | 0.78 | KLK5 (0.40) | F2CYP3A4THRBHSD17B10ABCB1 | |
| SCHEMBL8228152 | 0.77 | CYP3A4 (0.38) | AGTR2CYP3A4THRBHSD17B10MC4R | |
| Hydrochloric Acid SCHEMBL2429662 | 0.77 | CYP3A4 (0.38) | AGTR2F2CYP3A4THRBHSD17B10 | |
| SCHEMBL17099064 | 0.72 | AGTR2 (0.44) | AGTR2MC4RMC3RMC1RNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | AGTR2 822/4885F2 812/4885CYP3A4 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.